Group B streptococcus vaccine study will involve adult groups with and without underlying conditions
News
Immutep reveals commencement of vital phase 2 trial
Efti’s targeting activation of antigen-presenting cells delivers an adaptive immunity to fight cancer
SynaptixBio receives incurable disease research boost
The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development
Biomodal releases genetics and epigenetics solution
Product delivers epigenetic information from a single low-input DNA library without medical treatment
Oxford University malaria vaccine gets Ghana green light
Notable first clearance for R21/Matrix-M malaria vaccine for use in a specific country
Enhertu accepted for use across NHS Scotland
Decision will create opportunity for therapy to be used earlier in the treatment pathway
Aberdeen University and IMG join forces to accelerate diagnosis
Partnership will develop technology to screen and diagnose Lyme disease and diabetes
Almirall analyses wider well-being in dermatology study
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
Moderna cancer vaccine takes positive step
Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation
MSD’s Keytruda given go-ahead by SMC
Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer
Institute of Cancer Research embraces olaparib recommendation
Vital AstraZeneca therapy may transform lives of people with certain breast and prostate cancers
Positive study results for Infex’s RESP-X
Data demonstrates a sound safety and tolerability profile for therapy during phase 1 clinical trial
Ipsen reacts to NICE’s Cabometyx verdict
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Avacta doses first patient in pivotal phase 1a trial
Individual receives AVA6000 treatment as part of additional dose escalating study
Adcendo funding boosts antibody-drug conjugates development
Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP
